{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:37:29Z","timestamp":1763944649856,"version":"3.45.0"},"reference-count":13,"publisher":"CSIRO Publishing","issue":"6","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The high prevalence of asymptomatic Mycoplasma genitalium (MG) infection, combined with limited treatment options due to emerging antimicrobial resistance, raises important questions about the necessity of routine screening and treatment, particularly among men who have sex with men (MSM). This study aimed to determine the prevalence of macrolide and quinolone resistance in MG among HIV-positive MSM and assess its clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HIV-positive MSM were screened for sexually transmitted infections at the HIV clinic in Sheba Medical Center over a 43-month period, with demographic and clinical parameters recorded upon each visit. A subset of the patients underwent genetic resistance testing for macrolides and quinolones using real-time polymerase chain reaction assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 317 patients were screened during the study period. MG was detected in 80 (25.2%) patients, covering 150 episodes, at least once during follow-up. In 15 of these episodes (10.0%), patients reported symptoms that might be explained by MG infection. Among the 35 patients who were tested for resistance, 28 (82.3%) harbored macrolide resistance\u2013associated mutations, whereas 11 of 33 (33.3%) exhibited quinolone resistance\u2013associated mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings highlight a high prevalence of macrolide-resistant MG infections among HIV-positive MSM, with a notable proportion also exhibiting macrolide quinolone resistance. Given the asymptomatic nature of many MG infections and the increasing challenge of antimicrobial resistance, routine screening for MG in this population may provide limited clinical benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh25079","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:35:36Z","timestamp":1763944536000},"source":"Crossref","is-referenced-by-count":0,"title":["Resistance to macrolides and quinolones among HIV-positive MSM infected with Mycoplasma genitalium"],"prefix":"10.1071","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1262-1743","authenticated-orcid":true,"given":"Roee","family":"Launer Wachs","sequence":"first","affiliation":[{"name":"AThe Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel."},{"name":"BFaculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiraz","family":"Gefen Halevi","sequence":"additional","affiliation":[{"name":"CClinical Microbiology, Sheba Medical Center, Tel Hashomer, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Hamias","sequence":"additional","affiliation":[{"name":"CClinical Microbiology, Sheba Medical Center, Tel Hashomer, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Wieder-Feinsod","sequence":"additional","affiliation":[{"name":"AThe Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel."},{"name":"BFaculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladislav","family":"Litchevski","sequence":"additional","affiliation":[{"name":"AThe Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liraz","family":"Olmer","sequence":"additional","affiliation":[{"name":"DBio-Statistical and Bio-Mathematical Unit, The Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[{"name":"AThe Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel."},{"name":"BFaculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Amit","sequence":"additional","affiliation":[{"name":"BFaculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."},{"name":"CClinical Microbiology, Sheba Medical Center, Tel Hashomer, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itzchak","family":"Levy","sequence":"additional","affiliation":[{"name":"AThe Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel."},{"name":"BFaculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"suppl_2","key":"2025112319353308600_R1","doi-asserted-by":"publisher","first-page":"S382","DOI":"10.1093\/infdis\/jix172","article-title":"The unique microbiology and molecular pathogenesis of Mycoplasma genitalium.","volume":"216","author":"McGowin","year":"2017","journal-title":"J Infect Dis"},{"issue":"suppl_2","key":"2025112319353308600_R2","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.1093\/infdis\/jix145","article-title":"Mycoplasma genitalium infection in men.","volume":"216","author":"Horner","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"2025112319353308600_R3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263550","article-title":"Assessment of country implementation of the WHO global health sector strategy on sexually transmitted infections (2016\u20132021).","volume":"17","author":"Taylor","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"2025112319353308600_R4","first-page":"1","article-title":"Sexually transmitted infections treatment guidelines, 2021.","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR"},{"key":"2025112319353308600_R5","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S105469","article-title":"Mycoplasma genitalium infections: current treatment options and resistance issues.","volume":"10","author":"Sethi","year":"2017","journal-title":"Infect Drug Resist"},{"issue":"12","key":"2025112319353308600_R6","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010.","volume":"59","author":"Workowski","year":"2010"},{"issue":"11","key":"2025112319353308600_R7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/0956462416648585","article-title":"2016 European guideline on the management of non-gonococcal urethritis.","volume":"27","author":"Horner","year":"2016","journal-title":"Int J STD AIDS"},{"issue":"4","key":"2025112319353308600_R8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","article-title":"Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis.","volume":"94","author":"Baumann","year":"2018","journal-title":"Sex Transm Infect"},{"key":"2025112319353308600_R9","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America.","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"16","key":"2025112319353308600_R10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164924","article-title":"Prevalence and risk factors for antimicrobial resistance of Mycoplasma genitalium infections in a high-risk population.","volume":"13","author":"Hackett","year":"2024","journal-title":"J Clin Med"},{"issue":"9","key":"2025112319353308600_R11","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1093\/jac\/dkv136","article-title":"High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment.","volume":"70","author":"Nijhuis","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2025112319353308600_R12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/infdis\/jiz550","article-title":"Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC mutation G248T (S83I) and concurrent gyrA mutations.","volume":"221","author":"Murray","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"2025112319353308600_R13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1099\/mic.0.000830","article-title":"Mycoplasma genitalium: a review.","volume":"166","author":"Gnanadurai","year":"2020","journal-title":"Microbiology"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25079\/1824880\/sh25079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25079\/1824880\/sh25079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:35:37Z","timestamp":1763944537000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/22\/6\/SH25079\/265930\/Resistance-to-macrolides-and-quinolones-among-HIV"}},"subtitle":[],"editor":[{"given":"Somesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1071\/sh25079","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"article-number":"SH25079"}}